Sildenafil in primary pulmonary hypertension [5]

New England Journal of Medicine

Volumn 343, Issue 18, 2000, Pages 1342-

  Prasad, S ^a   Wilkinson, J ^a   Gatzoulis, M A ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SILDENAFIL;

CLINICAL FEATURE; DISEASE COURSE; ECHOCARDIOGRAPHY; HEART VENTRICLE FUNCTION; HUMAN; LETTER; LUNG FUNCTION TEST; PATIENT COMPLIANCE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ADMINISTRATION, ORAL; ADULT; HUMANS; HYPERTENSION, PULMONARY; MALE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES;

EID: 0034597646     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200011023431814     Document Type: Letter

References (4)

1. Urinary cGMP concentrations in severe primary pulmonary hypertension
2. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal
3. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension
4. Cyclic-GMP-binding, cyclic-GMP-specific phosphodiesterase (PDE5) gene expression is regulated during rat pulmonary development